Robotics Stock news
Microbot Medical Inc. (NASDAQ: MBOT) announced on October 6, 2026, that it signed a three--year exclusive distribution agreement with Medtechnica Ltd. to market and commercialize the LIBERTY® Endovascular Robotic System throughout Israel.
Strategic & Commercial Highlights:
- International Commercialization: Medtechnica, a leading medical device distributor in Israel, secures exclusive rights to commercialize the LIBERTY system following its regulatory registration approval with the Israeli Ministry of Health's AMAR Division.
- Order Timeline: Initial commercial orders under the agreement are anticipated during the fourth quarter of 2026 as Microbot expands manufacturing operations to address international demand.
- Clinical Value Proposition: LIBERTY is a single--use, remotely operated endovascular robotic platform engineered to enhance navigational precision in peripheral endovascular interventions while mitigating radiation exposure and physical strain for operating physicians.